摘要
肺癌是临床上最常见的恶性肿瘤之一,非小细胞肺癌(NSCLC)约占所有肺癌的80%。基于表皮生长因子受体(EGFR)而研发的靶向小分子酪氨酸激酶抑制剂(TKI)很大程度上改善了NSCLC患者的治疗效果,在临床上得到广泛的应用。而EGFR突变会使患者获得耐药性,干扰治疗。因此,对于EGFR突变的检测成为研究EGFR靶向药物治疗的热点。
Lung cancer is one of the most common malignancies in clinical practice. Non-small cell lung cancer （NSCLC） patients account for about 80% of all lung cancer ones. The targeted small molecule tyrosine kinase inhibitor （TKI） developed based on epidermal growth factor receptor （EGFR） has greatly improved the therapeutic effect among NSCLC patients and has been widely used clinically. EGFR mutations may promotethe drug resistance, which interference the treatment. Therefore, the detections of EGFR mutations have been intensively studied in the field of EGFR targeted drug treatment.
出处
《标记免疫分析与临床》
CAS
2017年第10期1197-1200,共4页
Labeled Immunoassays and Clinical Medicine
